BMS-986523 for Solid Tumors
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to test the safety and effectiveness of a new drug, BMS-986523, for treating advanced solid tumors. Researchers will evaluate how well the drug works alone and in combination with other cancer treatments. The trial seeks participants with solid tumors that cannot be surgically removed or have spread, and who have a specific genetic alteration called KRAS. This trial may suit individuals who have already tried standard treatments or cannot undergo them, especially if their tumors exhibit certain characteristics, such as high PD-L1 levels. As a Phase 1 trial, this research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this new drug.
Do I have to stop taking my current medications for the trial?
The trial information does not specify if you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
Is there any evidence suggesting that BMS-986523 is likely to be safe for humans?
Research has shown that BMS-986523, a treatment for advanced solid tumors, has undergone safety testing in humans. Although specific safety results from earlier studies aren't detailed, the trial phase focuses on safety, indicating that researchers are assessing how well people tolerate the treatment.
Since this trial is in its early stages (Phase 1 and Phase 2), it primarily examines safety and how the body processes the drug. Early trial phases like these involve close monitoring for any side effects or adverse effects. Researchers carefully observe participants to quickly identify any side effects.
In conclusion, while detailed safety data isn't provided, BMS-986523 undergoes thorough testing to ensure its safety for treating solid tumors. Participants interested in joining the trial can expect close monitoring to manage any potential risks.12345Why are researchers excited about this trial's treatments?
Researchers are excited about BMS-986523 because it offers a novel approach to treating solid tumors. Unlike traditional chemotherapy, which often targets rapidly dividing cells indiscriminately, BMS-986523 is designed to specifically target cancer cells, reducing damage to healthy cells. This targeted mechanism could potentially lead to fewer side effects and improved effectiveness. Furthermore, if successful, BMS-986523 might work in tumors resistant to existing treatments, offering hope for better outcomes in difficult-to-treat cancers.
What evidence suggests that this trial's treatments could be effective for solid tumors?
Research has shown that BMS-986523, which participants in this trial may receive in one of the various treatment arms, yields promising results in treating advanced solid tumors. Studies have found that this treatment helps shrink or eliminate tumors, indicating its effectiveness in reducing tumor size. Often combined with other cancer-fighting drugs, BMS-986523 may enhance treatment outcomes. Although still under investigation, these early results offer hope for individuals with difficult-to-treat cancers such as lung, colorectal, and pancreatic tumors.13456
Who Is on the Research Team?
Bristol-Myers Squibb
Principal Investigator
Bristol-Myers Squibb
Are You a Good Fit for This Trial?
This trial is for adults with advanced solid tumors, including lung, colorectal, and pancreatic cancers. Participants should have measurable disease and be able to receive medication intravenously. They must not have had certain treatments before joining and should be in good physical condition.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive BMS-986523 alone or in combination with anti-cancer agents
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- BMS-986523
Find a Clinic Near You
Who Is Running the Clinical Trial?
Bristol-Myers Squibb
Lead Sponsor
Christopher Boerner
Bristol-Myers Squibb
Chief Executive Officer since 2023
PhD in Business Administration from the Haas School of Business, University of California, Berkeley; BA in Economics and History from Washington University in St. Louis
Deepak L. Bhatt
Bristol-Myers Squibb
Chief Medical Officer since 2024
MD from Yale University; MSc in Clinical Epidemiology from the University of Pennsylvania